Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,051,530.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $531.74, for a total transaction of $5,051,530.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $172,519,320.82. This trade represents a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Up 0.2%

United Therapeutics stock opened at $525.82 on Friday. The firm has a market cap of $22.32 billion, a P/E ratio of 19.41, a P/E/G ratio of 1.75 and a beta of 0.58. The business has a fifty day moving average of $544.65 and a two-hundred day moving average of $532.54. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.63 earnings per share. Equities analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC purchased a new position in shares of United Therapeutics during the second quarter worth $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its position in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on UTHR shares. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $648.33.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.